Detection of HIV-1 in injection paraphernalia: Risk in an era of heightened awareness

AIDS Patient Care and STDs

Volumn 20, Issue 8, 2006, Pages 576-585

  Page, J Bryan ^a,b,c   Shapshak, Paul ^b   Duran, E Margarita ^b   Even, Gaelle ^b   Moleon Borodowski, Irina ^b   Llanusa Cestero, Renee ^b  

^a Department of Biology   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD EXAMINATION; BLOOD SAMPLING; COTTON; DRUG SELF ADMINISTRATION; ETHNOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; NEEDLE; REAL TIME POLYMERASE CHAIN REACTION; SYRINGE; VIRAL CONTAMINATION; VIRUS DETECTION; VIRUS LOAD; VIRUS TRANSMISSION; CULTURAL ANTHROPOLOGY; DISEASE TRANSMISSION; EQUIPMENT; ISOLATION AND PURIFICATION; POLYMERASE CHAIN REACTION; SUBSTANCE ABUSE; UNITED STATES; VIROLOGY;

ANTHROPOLOGY, CULTURAL; EQUIPMENT CONTAMINATION; FLORIDA; HIV INFECTIONS; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33748871960     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.20.576     Document Type: Article

References (57)

1. Gostin LO, Lazzarini Z, Jones ST. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users: A national survey on the regulation of syringes and needles. JAMA 1997;277:53-62.
2. Watters JK. A street-based outreach model of AIDS prevention for intravenous drug users: preliminary evaluation. Contemp Drug Prob 1987;14:411-423.
3. Shapshak P, McCoy CB, Rivers J, et al. Bleach effectively inactivates HIV-1 at short time intervals. J Acquir Immune Defic Syndr 1993;6:218-219.
4. Shapshak P, McCoy CB, Shah SM, et al. Preliminary laboratory studies on inactivation of HIV-1 in needles and syringes containing infected blood using undiluted household bleach. J Acquir Immune Defic Syndr 1994;7:754-759.
5. Braine N, DesJarlais DC, Ahmad S, Purchase D, Turner C. Long-term effects of syringe exchange on risk behavior and HIV prevention. AIDS Educ Prev 2004;16:264-275.
6. DesJarlais DC, Dehne K, Casabonda J. HIV surveillance among injecting drug users. AIDS 2001;15 (Suppl. 3):S13-S22.
7. Hartgers C, van Ameijden EJC, van den Hoek JAR, Coutinho RA. Needle sharing and participation in the Amsterdam syringe exchange program among HIV-seronegative injecting drug users. Public Health Rep 1992;107:675-681.
8. Ljungberg B, Andersson B, Christensson B, et al. Distribution of sterile equipment to IV drug abusers as part of an HIV prevention program. IV International Conference on AIDS, Stockholm, June 1988.
9. McCoy HV, Chitwood DD, Page JB, McCoy CB. Skills for HIV risk reduction: Evaluation of recall and performance in injecting drug users. Substance Use Misuse 1997;32:229-247.
10. Neuman MS, Johnson WD, Sernan S, et al. Review and meta-analysis of HIV prevention intervention research for heterosexual adult populations in the United States. J Acquir Immune Defic Syndr 2002;30:S106-S117.
11. Robertson R, Skidmore C, Roberts JJK. HIV infection in intravenous drug users: A follow-up study indicating changes in risk taking behavior. Br J Addict. 1988;83:387-391.
12. Schilling RF, Fontdevila J, Fernando D, El-Bassel N, Monterroso E. Proximity to needle exchange programs and HIV-related risk behavior among injection drug users in Harlem. Eval Prog Plan 2004;27:25-33.
13. Watters JK, Estilo MJ, Clark CL, Lorvick J: Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994;271:115-120.
14. Wolk J, Wodak A, Moriet A, et al. Syringe HIV seroprevalence and behavioral and demographic characteristics of intravenous drug users in Sydney, Australia, 1987. AIDS 1987;2:373-377.
15. Valenciano M, Emmanuelli J, Lert F. Unsafe injecting practices among attendees of syringe exchange programmes in France. Addiction 2001;96:597-606.
16. Ompad DC, Fuller CM, Vlahov D, Thomas D, Strathdee SA. Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Clin Infect Dis 2002;35:783-788.
17. Chitwood DD, Griffin DK, Comerford M, et al. Risk factors for HIV-1 seroconversion among injection drug users: A case-control study. Am J Public Health 1995;85:1538-1542.
18. Murrill CS, Prevots DR, Miller MS, Linley LA, Royalty JE, Gwinn M. Seroincidence Study Grp: Incidence of HIV among injection drug users entering drug treatment programs in four US cities. J Urban Health 2001;78:152-161.
19. Strathdee SA, Galai N, Safaiean M, et al. Sex differences in risk factors for HIV seroconversion among injection drug users: A 10-year perspective. Arch Intern Med 2001;161:1281-1288.
20. Nelson KE, Galai N, Safaeian M, Strathdee S, Celentano DD, Vlahov D. Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol 2002;156:641-653.
21. Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: Risk-factor analysis. Lancet 2001;357:1397-1401.
22. Kral AH, Lorvick J, Gee L, et al. Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol 2003;157:915-922.
23. Nicolosi A, Correa Leite ML, Molinari S, Mussico M, Sarraco A, Lazzarin A. Incidence and prevalence trends in HIV infection in intravenous drug users attending treatments centers in Milan and Northern Italy. J Acquir Immune Defic Syndr 1992;5:365-373.
24. Rebagliato M, Avi o MJ, Hernandez Aguado I, et al. Trends in incidence and prevalence of HIV-1 infection in intravenous drug users in Valencia, Spain. J Acquir Immune Defic Syndr 1995;8:297-301.
25. Page JB, Salazar JM. Needle use in Miami and Valencia: Observations of high and low availability. Med Anthropol Q 1999;13:413-435.
26. Page JB, Salazar JM. Where you sleep and where you shoot: Suggestive data from Valencia. Substance Use Misuse 2001;36:113-129.
27. Suligoi B, Magliochetti N, Nicoletti G, Pezzotti P, Rezza G. Trends in HIV prevalence among drug-users attending public drug-treatment centres in Italy: 1990-2000. J Med Virol 2004;73:1-6.
28. Celentano DD, Jittiwutikarn J, Razak MH, et al. HIV incidence among drug users in northern Thailand is limited to injectors. Presented at the annual AIDS Conference. Bangkok, Thailand: July, 2004.
29. Heimer R, Kaplan EH, Khoshnood K, Jariwala-Freeman B, Duncan B, Harima Y. Hepatitis in used syringes: The limits of sensitivity of techniques to detect HBV DNA, HCV RNA, and antibodies to HBV core and HCV antigens. J Infect Dis 1996;173:997-1000.
30. Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS 2000;14:717-726.
31. Fuller CM, Vlahov D, Latkin CA, Ompad DC, Celentano DD, Strathdee SA. Social circumstances of initiation of injection drug use and early shooting gallery attendance: Implications for HIV intervention among adolescent and young adult injection drug users. J Acquir Immune Defic Syndr 2003;32:86-93.
32. Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet 1996;348:987-991.
33. Evans JL, Hahn JA, Page-Shafer K, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health 2003;80:137-146.
34. Montgomery SB, Hyde J, De Rosa CJ, et al. Gender differences in HIV risk behaviors among young injectors and their social network members. Am J Drug Alcohol Abuse 2002;28:453-475.
35. Chitwood D, McCoy CB, Inciardi JA, et al. HIV seropositivity of needles from shooting galleries in South Florida. Am J Public Health 1990;80:150-152.
36. Abdala N, Reyes R, Carney JM, Heimer R. Survival of HIV-1 in syringes: Effects of temperature during storage. Subst Use Misuse 2000;35:1369-1383.
37. Clatts M, Heimer R, Abdala N, et al. HIV-1 transmission in injection paraphernalia: Heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr 1999;22:194-199.
38. Newmeyer J, Drew L, Miner R. HIV transmission I simulated conditions of sharing of hypodermic equipment. J Acquir Immune Defic Syndr 1990;3:1019-1021.
39. Trapido EJ, McCoy CB, Chitwood D, Resnick L. HIV-1 cultures from shooting gallery needles and syringes [Abstract, The 592]. 6th International AIDS Conference, San Francisco, CA: June 20-21, 1990.
40. Zamora AB, Rivera MO, Garcia-Algar O, et al. Detection of infectious human immunodeficiency type 1 virus in discarded syringes of intravenous drug users. Pediatr Infect Dis 1998;17:655-657.
41. Ariyoshi K, Bloor S, Bieniasz PD, Bourrelly M, Foxall R, Weber JN. Development of a rapid quantitative assay for HIV-1 plasma infectious viremia-culture-PCR (CPID). J Med Virol 1994;43:28-32.
42. Barker E, Mackewicz CE, Reyes-Teran G, et al. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood 1998;92:3105-3114.
43. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-733.
44. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-954.
45. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996;334:426-431.
46. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995;332:209-216.
47. Shah SM, Shapshak P, Rivers JE, et al. Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: A preliminary laboratory report. J Acquir Immune Defic Syndr 1996;11:301-306.
48. Shapshak P, Fujimura RK, Page JB, et al. HIV-1 RNA load in needles/syringes from shooting galleries in Miami: Preliminary laboratory report. Drug Alcohol Depend 2000;58:153-157.
49. Shapshak P, Duncan R, McCoy CB, Page JB. Real Time Reverse Transcriptase PCR Method for Quantification of HIV gag RNA. Front Biosci 2005;10:135-142.
50. Page JB, Chitwood DD, Smith PC, Kane N, McBride DC. Intravenous drug abuse and HIV infection in Miami. Med Anthropol Q 1990;4:56-71.
51. Fink L, Seeger W, Ermert L, et al. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 1998;4:1329-1333.
52. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001.
53. Lewin SR, Vesanen M, Kostrikis L, et al. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol 1999;73:6099-6103.
54. Needle RH, Coyle S, Cesari H, et al. HIV risk behaviors associated with the injection process: Multiperson use of drug injection equipment and paraphernalia in injection drug user networks. Subst Use Misuse 1998;33:2403-2423.
55. Thorpe LE, Bailey SL, Huo DZ, Monterroso ER, Ouellet LJ. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999) J Acquir Immune Defic Syndr 2001;27:71-78.
56. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young aclult injection drug users who share injection equipment. Am J Epidemiol 2002;155:645-653.
57. McCoy CB, Metsch LR, Chitwood DD, Shapshak P, Comerford ST. Parenteral transmission of HIV among injection drug users: Assessing the frequency of multi-person use of needles, syringes, cookers, cotton, and water. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:S25-S29.